Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion

This study has been terminated.

(No enrollements for more than 6 months in Phase II)

Sponsor:

Information provided by (Responsible Party):

Medtronic BRC

ClinicalTrials.gov Identifier:

NCT01088308

First received: March 11, 2010

Last updated: July 8, 2016

Last verified: July 2016

History of Changes

Purpose

This research study is a prospective, single-center, feasibility study designed to assess the possibility to detect hemodynamic changes during tachycardia episodes using tissue perfusion.

Condition	Intervention
Arrhythmias, Cardiac	Procedure: High rate atrial and vetricular stimulation Procedure: Ventricular Tachycardia induction


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion

Resource links provided by NLM:

MedlinePlus related topics: Arrhythmia

U.S. FDA Resources

Further study details as provided by Medtronic BRC:

Primary Outcome Measures:

Change in hemodynamic state during all tachycardia [ Time Frame: <3 hours ] [ Designated as safety issue: No ]
The primary objective is to demonstrate for all tachycardia (supra-ventricular and ventricular tachycardia) a 90 % [two sided confidence interval of 75-100 %] agreement between the true hemodynamic state (stable or unstable) derived from arterial blood pressure measurement and the hemodynamic state determined by tissue perfusion

Secondary Outcome Measures:

Change in hemodynamic state during SVT [ Time Frame: <3 hours ] [ Designated as safety issue: No ]
The secondary objective is to demonstrate for supra-ventricular tachycardia a 90 % [two sided confidence interval of 75-100 %] agreement between the true hemodynamic state (stable or unstable) derived from arterial blood pressure measurement and the hemodynamic state determined by tissue perfusion.


Enrollment:	18
Study Start Date:	March 2010
Study Completion Date:	May 2012
Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Single Arm All Patients underwent Intervention.	Procedure: High rate atrial and vetricular stimulation The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle. Other Name: High rate pacing Procedure: Ventricular Tachycardia induction A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle. Other Name: VT induction

Arms

Assigned Interventions

Experimental: Single Arm

All Patients underwent Intervention.

Procedure: High rate atrial and vetricular stimulation

The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.

Other Name: High rate pacing

Procedure: Ventricular Tachycardia induction

A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.

Other Name: VT induction

Detailed Description:

This study is being conducted to evaluate the feasibility to detect hemodynamic changes induced by supra-ventricular or ventricular tachycardia (SVT or VT) using tissue perfusion. Patients with a standard indication for either an electrophysiological study or an implantable cardioverter defibrillators(ICD) implant can be included into this study. Tissue perfusion and arterial blood pressure will be monitored and recorded throughout the electrophysiological procedure or ICD implant testing.

The study will be conducted in two consecutive phases. After completion of study phase I the study phase II will commence. Study phase I will be an acute non-invasive study in patients with an indication for an electrophysiological study, in whom tissue perfusion will be measured non-invasively with an epi-cutaneous tissue perfusion sensor. Phase II will be an acute invasive study in patients with an indication for the implantation of an ICD, in whom the tissue perfusion sensor will be placed in the surgically prepared device pocket on the muscular pectoralis or between the muscular pectoralis major and muscular pectoralis minor.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Indication for: an electrophysiological study with ventricular stimulation OR the implantation of an implantable cardioverter defibrillator (ICD)
Patient is at least 18 years old.
Patient is able and willing to give informed consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01088308

Locations


Germany
Universitätsklinikum
Aachen, Germany, 52074

Sponsors and Collaborators

Medtronic BRC

Investigators


Principal Investigator:	Emilia Stegemann, Dr. med	Universitätsklinikum Aachen

More Information


Responsible Party:	Medtronic BRC
ClinicalTrials.gov Identifier:	NCT01088308 History of Changes
Other Study ID Numbers:	TPS1010
Study First Received:	March 11, 2010
Last Updated:	July 8, 2016
Health Authority:	Germany: Ethics Commission
Individual Participant Data
Plan to Share IPD:	Undecided

Additional relevant MeSH terms:


Tachycardia Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes

ClinicalTrials.gov processed this record on September 28, 2016

To Top